Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume 382, Issue 21, Pages 1969-1973Publisher
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMp2005630
Keywords
-
Categories
Ask authors/readers for more resources
An ideal vaccine platform would support development from viral sequencing to clinical trials in less than 16 weeks, demonstrate elicitation of consistent immune responses across pathogens, and be suitable for large-scale manufacturing using a pathogen-agnostic platform.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
